Science says it's safe, but some in France don't trust AstraZeneca vaccine
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
SUNDAY, MAY 22, 2022
SUNDAY, MAY 22, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Science says it's safe, but some in France don't trust AstraZeneca vaccine

Coronavirus chronicle

Reuters
08 March, 2021, 09:00 pm
Last modified: 08 March, 2021, 09:04 pm

Related News

  • On 'burkini' row, it is French government vs city of Grenoble
  • Macron picks Elisabeth Borne as new prime minister
  • Macron suggests new European entity
  • France's Macron sworn in for second term as president
  • Armed robbers strike Chanel jewellery store in Paris and flee on motorbikes

Science says it's safe, but some in France don't trust AstraZeneca vaccine

According to the most recent data made available by the French health ministry, for the end of February, France was using 24% of its AstraZeneca doses, compared with 82% for vaccines made by Pfizer/BioNTech and 37% for the Moderna shot

Reuters
08 March, 2021, 09:00 pm
Last modified: 08 March, 2021, 09:04 pm
The vaccine allegedly "stimulates broad antibody and T cell functions Photo: Medical Xpress
The vaccine allegedly "stimulates broad antibody and T cell functions Photo: Medical Xpress

A 60-year-old recovering from breast cancer, Paris resident Nadine Roger is at high-risk from Covid-19 and wants to get vaccinated as soon as possible. Yet when she was offered the vaccine manufactured by AstraZeneca she turned it down.

"The AstraZeneca (shot) frightens me," she said. Roger, a medical technician, said she would wait instead for the shot made by US firm Johnson & Johnson, which has not yet been approved by European regulators.

According to the most recent data made available by the French health ministry, for the end of February, France was using 24% of its AstraZeneca doses, compared with 82% for vaccines made by Pfizer/BioNTech and 37% for the Moderna shot.

That is partly due to logistical bottlenecks, but also because some French people don't trust the AstraZeneca shot - despite multiple scientific studies that indicate it is safe and effective - according to interviews Reuters conducted with eight people involved in France's vaccine rollout.

They said some of those offered the vaccine were worried about side-effects, sceptical it was effective against new variants of Covid-19, and confused by shifting evidence on how well it works for older people.

The AstraZeneca vaccine had a bumpy genesis.

European regulators recommended it not be used for people over 65, citing a lack of data. French President Emmanuel Macron was quoted as saying the shot was "quasi-effective" and the French regulator called on hospitals to stagger inoculations of their staff after side effects led frontline workers to call in sick.

"All that sent out the wrong signal to health workers, but also the rest of the population," said Jacques Battistoni, head of the largest general practitioners' union in France.

CHANGING TACK

To be sure, France is one of the most vaccine-sceptic countries globally, though surveys have showed the proportion of the public intending to get inoculated increasing.

Like other wealthy countries, France has made the AstraZeneca shot a pillar of its vaccine rollout. With all the big vaccine makers experiencing production problems, countries cannot afford for people to snub one of the shots.

A health ministry official and two doctors involved in the rollout said the uptake was accelerating as logistics improve and people get used to the AstraZeneca shot.

AstraZenaca doses were initially to be delivered to hospitals and vaccination centres for the inoculation of healthcare workers, and to general practitioners for the vaccination of 50 to 64-year-olds with pre-existing conditions.

In the first week of the AstraZenaca rollout, which coincided with the start of school holidays, GPs ordered fewer than half of their allocated doses.

The president of AstraZeneca France, Olivier Nataf, told the weekly Journal du Dimanche at the weekend that his company's vaccine was entirely effective against severe Covid-19 infections and 80% effective in preventing hospitalizations.

"Confusions and disappointments can arise. Many are already resolved," he told the newspaper. "There may be others. But the enemy remains the pandemic. Any controversy diminishes our ability to overcome it."

European regulators have concluded the side-effects cause by the AstraZenaca vaccine are not a cause to doubt its safety. A study in Scotland covering 5.4 million people showed it, and the Pfizer vaccine, were highly effective in preventing severe infections.

France, Germany and Italy have changed tack and are now giving the vaccine to people over 65.

Macron said last month the AstraZeneca jab was effective, and he would take it if offered.

'SECOND-RATE VACCINE'

But some doubts linger. Malika, a 54-year-old who works in a clinic for homeless people near Paris, said she turned down the AstraZeneca vaccine when offered it.

"I thought to myself: 'I don't really see the point of getting vaccinated with a second-rate vaccine'," said Malika, who did not want her family name published.

She said her mind was made up when a colleague had the shot and experienced side-effects. Malika said wanted to have the Pfizer jab, currently reserved for over-75s, instead.

Roger, the cancer survivor, said she lived alone, so was worried about coming down with a fever, one of the possible side-effects from Covid-19 vaccines, and had doubts about the AstraZeneca vaccine's efficacy against new variants.

But the big drawback, she said, was that she would have to wait until getting a second AstraZeneca shot in May to feel fully protected, an issue that would not arise with the one-shot Johnson & Johnson vaccine.

She has been to Yemen, Mali, and Madagascar, and the shelves of her home are decorated with artefacts she brought home. Since her cancer diagnosis, she said she realised she needed to make the most of the time she has, and get back on the road.

"Right now, AstraZeneca doesn't allow me to do that."

Covid-19 Vaccination / AstraZeneca Covid-19 Vaccine / Coornavirus / France

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Project delays: The Sinohydro style 
    Project delays: The Sinohydro style 
  • An image created during an investigation into an outbreak of monkeypox, which took place in the Democratic Republic of the Congo (DRC), 1996 to 1997, shows the hands of a patient with a rash due to monkeypox.(REUTERS)
    WHO expects more cases of monkeypox to emerge globally
  • Photo: Courtesy
    Misfit Technologies: A Singaporean startup rooted firmly in Bangladesh

MOST VIEWED

  • People wearing protective face masks walk on a street, following new cases of the coronavirus disease (Covid-19), in Shanghai, China August 25, 2021. REUTERS/Aly Song
    Shanghai district to require all shops to shut, residents to stay home
  • Photo: Courtesy
    Covax calls for urgent action to close vaccine equity gap
  • Photo: BSS/AFP
    Covax calls for urgent action to close vaccine equity gap
  • Photo: Collected
    Thousands of Covid-negative Beijing residents sent to quarantine
  • A man checks phone at Lujiazui financial district in Pudong, Shanghai, China March 14, 2019. Photo :Reuters
    Shanghai inches towards Covid lockdown exit, Beijing plays defence
  • North Korean leader Kim Jong Un delivers opening remarks during the 2nd Conference of Secretaries of Primary Committees of the Workers' Party of Korea (WPK), in this photo released on February 27, 2022 by North Korea's Korean Central News Agency (KCNA). KCNA via REUTERS/File Photo
    N Korea reports over 200,000 fever cases for 5th day amid Covid wave

Related News

  • On 'burkini' row, it is French government vs city of Grenoble
  • Macron picks Elisabeth Borne as new prime minister
  • Macron suggests new European entity
  • France's Macron sworn in for second term as president
  • Armed robbers strike Chanel jewellery store in Paris and flee on motorbikes

Features

Warah uses three types of khadi material: a sheer and light one, a medium count and a thicker one.

Warah: Embroidered with culture and womanhood

1h | Mode
Photo: Courtesy

Misfit Technologies: A Singaporean startup rooted firmly in Bangladesh

1h | Panorama
The Buffalo shooter targeted Black people, linking mass migration with environmental degradation and other eco-fascist ideas. Photo: Reuters

Eco-fascism: The greenwashing of the far right

21h | Panorama
Green-backed Heron on a tilting stalk. Photo: Enam Ul Haque

Green-backed Heron: Nothing but a prayer to catch a fish  

23h | Panorama

More Videos from TBS

CV or Resume: Which one to create for job application

CV or Resume: Which one to create for job application

1h | Videos
Wheat prices double in India

Wheat prices double in India

15h | Videos
Is Washington-Moscow agreement possible?

Is Washington-Moscow agreement possible?

15h | Videos
Pigeon exhibition for the first time in Gazipur

Pigeon exhibition for the first time in Gazipur

19h | Videos

Most Read

1
Tk100 for bike, Tk2,400 for bus to cross Padma Bridge
Bangladesh

Tk100 for bike, Tk2,400 for bus to cross Padma Bridge

2
A packet of US five-dollar bills is inspected at the Bureau of Engraving and Printing in Washington March 26, 2015. REUTERS/Gary Cameron
Banking

Dollar hits Tk100 mark in open market

3
The story of Bangladesh becoming a major bicycle exporter
Industry

The story of Bangladesh becoming a major bicycle exporter

4
PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire
Crime

PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire

5
BSEC launches probe against Abul Khayer Hero and allies
Stocks

BSEC launches probe against Abul Khayer Hero and allies

6
The reception is a volumetric box-shaped room that has two glass walls on both the front and back ends and the other two walls are adorned with interior plants, wood and aluminium screens. Photo: Noor-A-Alam
Habitat

The United House: Living and working inside nature

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab